We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Union Pacific (UNP) to Post Q1 Earnings: What's in Store?
Read MoreHide Full Article
Union Pacific Corporation (UNP - Free Report) is slated to release first-quarter 2020 results on Apr 23, before the market opens.
The Zacks Consensus Estimate for first-quarter earnings has been revised 2.6% downward in the past 60 days. Against this backdrop, let’s take a look at the factors that might have shaped the company’s March quarter performance.
Weak freight environment, perhaps worsened by the coronavirus outbreak, is likely to have weighed on volumes in the first quarter. Notably, the Zacks Consensus Estimate for total volumes in the first quarter indicates a 4.4% decline from the sequential quarter’s reported figure. Consequently, freight revenues (accounting for bulk of the top line) are also expected to have been hurt. The consensus mark for freight revenues implies a 4.6% fall from that reported in the fourth quarter of 2019.
Moreover, key segments like Premium and Energy are expected to have performed disappointingly in the soon-to-be-reported quarter. While decline in U.S. light vehicle sales is expected to have affected the Premium division, suppression in the coal market due to low natural gas prices and weak export demand is anticipated to have hampered the Energy division. The Zacks Consensus Estimate for Premium revenues indicates an 11.7% decrease from the sequential quarter’s reported figure. The same for energy revenues suggests a 5.5% decline from the previous quarter’s reported number.
However, the company’s cost-reduction efforts are anticipated to have driven the bottom line. Cost savings might also reflect on the operating ratio (operating expenses as a percentage of revenues).
The proven Zacks model does not conclusively predict an earnings beat for Union Pacific this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates. However, that is not the case here as elaborated below. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: Union Pacific has an Earnings ESP of +1.02% as the Most Accurate Estimate is pegged at $1.88, higher than the Zacks Consensus Estimate of $1.86. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Union Pacific carries a Zacks Rank #4 (Sell).
Highlights of Q4 Earnings
In the last reported quarter, the company witnessed a negative earnings surprise of 0.5%. Moreover, the bottom line decreased 4.7% on a year-over-year basis. Although operating revenues surpassed the Zacks Consensus Estimate, it declined 9% due to 10% decrease in freight revenues. Total business volumes dropped 11%.
Stocks to Consider
Investors interested in the broader Transportation sector may consider Covenant Transportation Group, Inc. , Valaris plc (VAL - Free Report) and Golar LNG Limited (GLNG - Free Report) as these stocks possess the right combination of elements to beat on earnings this reporting cycle.
Covenant Transportation has an Earnings ESP of +10.00% and a Zacks Rank #3.
Valaris has an Earnings ESP of +0.27% and aZacks Rank of 3.
Golar LNG has an Earnings ESP of +1,100.00% and is Zacks #3Ranked.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Union Pacific (UNP) to Post Q1 Earnings: What's in Store?
Union Pacific Corporation (UNP - Free Report) is slated to release first-quarter 2020 results on Apr 23, before the market opens.
The Zacks Consensus Estimate for first-quarter earnings has been revised 2.6% downward in the past 60 days. Against this backdrop, let’s take a look at the factors that might have shaped the company’s March quarter performance.
Weak freight environment, perhaps worsened by the coronavirus outbreak, is likely to have weighed on volumes in the first quarter. Notably, the Zacks Consensus Estimate for total volumes in the first quarter indicates a 4.4% decline from the sequential quarter’s reported figure. Consequently, freight revenues (accounting for bulk of the top line) are also expected to have been hurt. The consensus mark for freight revenues implies a 4.6% fall from that reported in the fourth quarter of 2019.
Moreover, key segments like Premium and Energy are expected to have performed disappointingly in the soon-to-be-reported quarter. While decline in U.S. light vehicle sales is expected to have affected the Premium division, suppression in the coal market due to low natural gas prices and weak export demand is anticipated to have hampered the Energy division. The Zacks Consensus Estimate for Premium revenues indicates an 11.7% decrease from the sequential quarter’s reported figure. The same for energy revenues suggests a 5.5% decline from the previous quarter’s reported number.
However, the company’s cost-reduction efforts are anticipated to have driven the bottom line. Cost savings might also reflect on the operating ratio (operating expenses as a percentage of revenues).
Union Pacific Corporation Price and EPS Surprise
Union Pacific Corporation price-eps-surprise | Union Pacific Corporation Quote
Earnings Whispers
The proven Zacks model does not conclusively predict an earnings beat for Union Pacific this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates. However, that is not the case here as elaborated below. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: Union Pacific has an Earnings ESP of +1.02% as the Most Accurate Estimate is pegged at $1.88, higher than the Zacks Consensus Estimate of $1.86. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Union Pacific carries a Zacks Rank #4 (Sell).
Highlights of Q4 Earnings
In the last reported quarter, the company witnessed a negative earnings surprise of 0.5%. Moreover, the bottom line decreased 4.7% on a year-over-year basis. Although operating revenues surpassed the Zacks Consensus Estimate, it declined 9% due to 10% decrease in freight revenues. Total business volumes dropped 11%.
Stocks to Consider
Investors interested in the broader Transportation sector may consider Covenant Transportation Group, Inc. , Valaris plc (VAL - Free Report) and Golar LNG Limited (GLNG - Free Report) as these stocks possess the right combination of elements to beat on earnings this reporting cycle.
Covenant Transportation has an Earnings ESP of +10.00% and a Zacks Rank #3.
Valaris has an Earnings ESP of +0.27% and aZacks Rank of 3.
Golar LNG has an Earnings ESP of +1,100.00% and is Zacks #3Ranked.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>